20 completed, 3 terminated, 3 unknown, 2 recruiting. 29 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 29 | Completed 20, Terminated 3, Unknown 3, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow Secondary Hyperparathyroidism: new trials by email Literature Review of Secondary Hyperparathyroidism trials Research Report on Secondary Hyperparathyroidism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis PLS240, Standard of Care - Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism | Phase 3 | Not yet recruiting | Pathalys Pharma | 56 | 2026-10-30 | 2026-10-22 |
| The Trial of SHR6508 in Secondary Hyperparathyroidism SHR6508 plus oral placebo tablets, Cinacalcet plus intravenous placebo - Secondary Hyperparathyroidism | Phase 3 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 498 | 2024-06-14 | 2025-12-12 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End Stage Kidney Disease | Phase 3 | Completed | Pathalys Pharma | 412 | 2023-05-15 | 2025-09-09 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD) | Phase 3 | Completed | Pathalys Pharma | 362 | 2023-04-28 | 2025-09-09 |
| Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism CTAP101, Placebo - Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 | Phase 3 | Terminated | OPKO Health, Inc. | 2 | 2023-01-31 | 2025-07-25 |
| A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism Paricalcitol, Placebo - Secondary Hyperparathyroidism | Phase 3 | Unknown | Chengdu Suncadia Medicine Co., Ltd. | 84 | 2022-02-01 | 2022-02-10 |
| Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Teriparatide - Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder | Phase 3 | Completed | Saint Petersburg State University, Russia | 20 | 2021-03-01 | 2022-11-10 |
| A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis Etelcalcetide - Secondary Hyperparathyroidism | Phase 3 | Recruiting | Amgen | 24 | 2019-12-20 | 2026-08-21 |
| A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis Etelcalcetide, Standard of Care - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Recruiting | Amgen | 56 | 2019-04-29 | 2026-02-27 |
| Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia KHK7580, Cinacalcet Hydrochloride - Secondary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 404 | 2019-04-09 | 2022-04-25 |
| Phase 3 Study of SK-1403 SK-1403, Placebo - Secondary Hyperparathyroidism | Phase 3 | Completed | Sanwa Kagaku Kenkyusho Co., Ltd. | 153 | 2019-01-21 | 2020-03-09 |
| SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis SK-1403 - Secondary Hyperparathyroidism | Phase 3 | Completed | Sanwa Kagaku Kenkyusho Co., Ltd. | 157 | 2018-09-13 | 2020-03-09 |
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Etelcalcetide, Cinacalcet - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Completed | Amgen | 637 | 2018-05-15 | 2021-04-30 |
| Phase 3 Study of KHK7580 KHK7580 - Secondary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 39 | 2015-09-29 | 2017-07-05 |
| Phase 3 Study of KHK7580 KHK7580 - Secondary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 137 | 2015-09-28 | 2017-07-05 |
| Phase 3 Study of KHK7580 KHK7580, KRN1493 - Secondary Hyperparathyroidism | Phase 2 / Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 634 | 2015-09-01 | 2017-03-24 |
| Comparison of Total Parathyroidectomy With and Without Autotransplantation total PTX without autotransplantation, total PTX with autotransplantation - Secondary Hyperparathyroidism | Phase 3 | Unknown | The Second Hospital of Anhui Medical University | 96 | 2015-09-01 | 2015-08-31 |
| Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet Etelcalcetide, Cinacalcet, Oral Placebo - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Completed | Amgen | 683 | 2013-08-13 | 2019-07-18 |
| A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis paricalcitol - End-Stage Renal Disease, Secondary Hyperparathyroidism | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 13 | 2011-10-01 | 2018-07-02 |
| Pediatric Chronic Kidney Disease Safety and Efficacy cinacalcet capsule, placebo, Standard of Care - Chronic Kidney Disease, Hyperparathyroidism | Phase 3 | Terminated | Amgen | 43 | 2011-06-28 | 2020-06-29 |
Showing 20 of 29. Sign in to see all of them.
Hyperparathyroidism, Secondary (29) · Renal Insufficiency, Chronic (10) · Kidney Failure, Chronic (7) · Hyperparathyroidism (2) · Kidney Diseases (2) · Vitamin D Deficiency (2) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Coronary Artery Disease (1) · Hypocalcemia (1) · Hypoparathyroidism (1) · Osteoporosis (1) · Osteoporotic Fractures (1) · Parathyroid Diseases (1) · Recurrence (1) · Renal Insufficiency (1)
Endocrine System Diseases (29) · Parathyroid Diseases (28) · Hyperparathyroidism (27) · Disease Attributes (18) · Pathologic Processes (18) · Pathological Conditions, Signs and Symptoms (18) · Chronic Disease (17) · Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Male Urogenital Diseases (17) · Urogenital Diseases (17) · Urologic Diseases (17) · Kidney Diseases (15) · Renal Insufficiency (15) · Renal Insufficiency, Chronic (6)
Cinacalcet (11) · etelcalcetide hydrochloride (4) · paricalcitol (4) · Standard of Care (3) · Calcium (1) · Teriparatide (1) · Transplantation, Autologous (1) · maxacalcitol (1) · upacicalcet (1)
Amgen (9) · Kyowa Kirin Co., Ltd. (4) · Pathalys Pharma (3) · AbbVie (prior sponsor, Abbott) (2) · OPKO Health, Inc. (2) · Sanwa Kagaku Kenkyusho Co., Ltd. (2) · Chengdu Suncadia Medicine Co., Ltd. (1) · Creighton University (1) · ENRICO VERRINA (1) · Saint Petersburg State University, Russia (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1) · The Second Hospital of Anhui Medical University (1) · Thomas Jefferson University (1)
United States (9) · Japan (6) · Poland (5) · Spain (5) · China (4) · Portugal (4) · Russia (4) · Belgium (3) · Germany (3) · Hungary (3) · Italy (3) · South Korea (3) · Taiwan (3) · Bulgaria (2) · Czechia (2)
Akhtar Ashfaq, MD (1) · Ann Eldred, MD (1) · David J Whellan, MD MHS (1) · Enrico E. Verrina, MD (1) · Joan M Lappe, Ph.D (1) · Joel Melnick, MD (1) · Kazuya Kobayashi, BA (1)
PMID 11576947, PMID 15689407, PMID 15828905, PMID 16105056, PMID 17556697, PMID 18793528, PMID 20435429, PMID 22202993, PMID 23222688, PMID 24128439, PMID 25404192, PMID 25710802, PMID 25851955, PMID 25887067, PMID 25950238, PMID 26059012, PMID 27080930, PMID 28332096, PMID 29525393, PMID 30955188, PMID 35176038, PMID 36512619, PMID 37696667, PMID 41078042
2023 (2), 2009 (1), 2017 (1)